Best GLP-1 for Sleep Apnea

By Alsen Walker · Editorially reviewed on 25 August 2026 · Not medically reviewed by a clinician

Tirzepatide has an approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity, which is why this question has a different answer from most. The sleep study result is what unlocks it: without objective confirmation of severity, a request is assessed as weight management instead.

For how this fits alongside the other comparisons, and what actually decides the choice, see Comparing GLP-1 Medications: How to Actually Choose.

Why weight and sleep apnea are linked

Excess tissue around the upper airway contributes to obstruction during sleep, and weight loss frequently reduces the severity of obstructive sleep apnea.

That relationship is the reason a weight-acting medication has an apnea indication at all, and it is also why treating apnea has value beyond sleep: untreated apnea carries cardiovascular consequences of its own.

What you need documented

A diagnosis of moderate-to-severe obstructive sleep apnea, established by a sleep study, either in-lab or a home test. Clinical suspicion is not enough; the reviewer wants the objective result.

Obesity documented alongside it.

And a plan that covers the product for that indication, since permission to cover is not obligation to cover.

If you have never been tested

Untreated sleep apnea is common and frequently undiagnosed in people with obesity. Heavy snoring, waking unrefreshed, witnessed breathing pauses and daytime sleepiness are the usual signs.

Raise it with your clinician if that describes you, and pursue testing because you may have a condition worth treating, not because you want a prescription covered. A study pushed for to unlock coverage may come back negative, and the honest reason for testing is the better one.

What happens as you lose weight

Apnea severity often improves, which can mean CPAP pressure settings need adjusting. A setup that was comfortable can start to feel wrong, and that is a reason for review rather than abandonment.

Whether treatment can eventually be reduced or stopped is decided by repeat testing, not by how you feel.

Mild apnea

The indication specifies moderate-to-severe, so mild obstructive sleep apnea generally falls outside it. That does not mean mild apnea is unimportant, only that this particular coverage route is not available.

Frequently asked questions

Which drug has the sleep apnea indication?
Check current prescribing information, since indications are product-specific and change.

Does mild apnea qualify?
Generally not. The indication specifies moderate-to-severe.

Can I stop CPAP if I lose weight?
Only after repeat testing and a clinician saying so.

Will Medicare cover it for apnea?
A separate approved indication sits outside the weight loss exclusion, though your plan’s formulary still decides. Check directly.

Do I need a repeat sleep study?
Often useful after significant weight loss. Ask your clinician.

What if my plan refuses?
A formulary exception request filed by your prescriber is the mechanism, and appeal rights apply.

Sources and further reading

1. Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024. pubmed.ncbi.nlm.nih.gov
2. US Food and Drug Administration. FDA approves first medication for obstructive sleep apnea (Zepbound), December 2024. www.fda.gov
3. MedlinePlus (US National Library of Medicine). Semaglutide injection: drug information. medlineplus.gov
4. MedlinePlus (US National Library of Medicine). Tirzepatide injection: drug information. medlineplus.gov
5. National Institute of Diabetes and Digestive and Kidney Diseases (NIH). Prescription medications to treat overweight and obesity. www.niddk.nih.gov

GLP1Hub content is for general information and is not medical advice. Prices and coverage rules change often, so confirm current details with the provider, your insurer and your prescriber. See our editorial standards and medical disclaimer.